UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: October 2024

 

Commission file number: 001-36578

 

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

Annual General Meeting of Shareholders

 

On October 31, 2024, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), convened its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”); however, due to the lack of a quorum, the Annual Meeting was adjourned for one week. Accordingly, the Annual Meeting will be reconvened on Thursday, November 7, 2024, beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Therapeutics Ltd.
  (Registrant)
     
  By: /s/ Oren Hershkovitz
  Name: Oren Hershkovitz
  Title: Chief Executive Officer
     
Date: October 31, 2024    
     

 

 

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Enlivex Therapeutics Charts.
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Enlivex Therapeutics Charts.